EGFR mutations have been identified in triple-negative breast cancers in a small study highlighting the possible application of oral EGFR tyrosine kinase inhibition therapy in selected breast cancer patients [19]. The gene discussed is EGFR; the disease is triple-negative breast carcinoma.